Leap Therapeutics Inc (LPTX)

[trustbutverifyit]

Raymond James analyst David Novak upgrades Leap Therapeutics (NASDAQ:LPTX) from Market Perform to Outperform and announces $2.5 price target.

[cheekitlim]

BOOOOOOOOOOOOOOMMMMMMMMMM!!!!!!!!!!!!

[cheekitlim]

$LPTX The company is screaming for a buyout.

They have even secured the votes from a majority shareholder to make the deal look very serious. Well, other big pharmas looking to go into this lucrative area has until 8 Jan 2020 (i.e. closing date for the deal) to make a counter offer. IMHO, $6-8 per share buyout sounds about right.

[cheekitlim]

Major chinese media outlets now reporting on this.

https://money.udn.com/money/story/9529/4266873

https://finance.sina.cn/2020-01-03/detail-iihnzahk1832804.d.html?from=wap

[cheekitlim]

$LPTX CFO tweeted this out:

After gaining approval of its anti-PD-1 mAb in China, BeiGene is already looking to add a complementary cancer therapy to its pipeline. BeiGene gained an option to Leap Therapeutic's DKK1 inhibitor in Asia, except Japan $LPTX $BGNE https://t.co/hyDilWOVFM

— BioCentury (@BioCentury) January 4, 2020

"Onsi said Leap is unaware of any other DKK1 inhibitors in development for gastric cancer."

HODL

[cheekitlim]

New financing will extend cash runway into the second half of 2021

https://www.bizjournals.com/boston/news/2020/01/03/cash-strapped-biotech-signs-deal-with-chinese.html?ana=yahoo&yptr=yahoo

[cheekitlim]

Company is totally vindicated for making the strategic decision to deprioritize further development of TRX518 in order to focus on the more advanced DKN-01 program.

NOW IS THE TIME TO BUY!!!

[cheekitlim]

MEGA News: Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity financing with BeiGene and two institutional investors

https://ih.advfn.com/stock-market/NASDAQ/leap-therapeutics-LPTX/stock-news/81455588/leap-therapeutics-and-beigene-announce-exclusive-o

[ClayTrader]

* * $LPTX Video Chart 01-03-2020 * *

Link to Video - click here to watch the technical chart video

[cheekitlim]

POWER HOUR!!!!!!

[cheekitlim]

$10 COMING??????

[cheekitlim]

BOOOOOOOOOOOOOOOOOOOOOMMMMMMMMMM!!!!!!!!!

[StocktonCA]

Baker bros advisory llc bought 1 million shares of this in feb.

check out www.j3sg.com
insert there name under institutions
they are managing a 14 billion dollar account. it has grow massively

[stock1ace1]

In 2.20 news !!!

[TFMG]

LPTX - BREAK OUT - POSSIBLE 40% MOVE

Leap Therapeutics , Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Leap Therapeutics , Inc. ( LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: https://finance.yahoo.com/news/leap-ther...)

SHORT INTEREST
2.1M 07/15/19

P/E Current
-0.95

P/E Ratio (with extraordinary items)
-1.34

Average Recommendation: BUY

Average Target Price: 9.00

[Glider549]

I never said it wasn't.
I just said I watched it sail past me the other day.
In other words, I missed out.

[WBillCody]

Sailed? You’re kidding, right? Dig a bit deeper and you’ll see why it’s grossly under appreciated and under valued

[Glider549]

I put this on my 'watch' list and watched it sail without me,,, *sigh*

[Nikolai771]

I’d be a millionaire if half of the 52 week price predictions on yahoo were correct.

[Ryoko]

Beware of price targets. They are basically crap predictors foisted by "analysts" with the goal of moving the stock price one way or another. Actually, I've learned to completely ignore "analysts" and their recommendations since their analysis is typically worthless.

[hawkeye45691]

News is out and very positive: https://seekingalpha.com/pr/17461982-leap-therapeutics-reports-clinical-update-2018-financial-results

Not a bad time to get into this one as it has a nice $17/share price target.

[Ryoko]

Unless the earnings has a positive surprise, I'm thinking this recent bump is going to decay back to the $1.40 level.

[GEEZ]

News on earnings dues soon thats what is holding this up

[Corytrades]

Ready to leap back in. When does bottom hit, and any thoughts on the near future news.

[GEEZ]

Market makers dont care about who owns what they are crooks... volume is needed

[J0shy]

Insiders own a ton @ $1.75. I think they know more than us

[GEEZ]

If earnings are bad ...its heading down.....shorts are on this

[J0shy]

Lol you be waiting a while

[GEEZ]

I will check out and buy back at 1.40

[LQMTinvestor2018]

Earnings are meaningless in a company like this, especially considering they just raised money via offering. Check back in a few weeks and it will be $4+

[GEEZ]

Dont think.we will see any good earnings here timebto.bail

[LQMTinvestor2018]

Yea, that’s alright, once we see a bottom I’ll add more

[GEEZ]

Markst makers trading 0 share blocks to take us down

[LQMTinvestor2018]

Let’s gooooo!

[whytestocks]

News: $LPTX Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

CAMBRIDGE, Mass. , March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annu...

Find out more https://marketwirenews.com/news-releases/leap-therapeutics-presents-at-society-of-gynecologic-oncology-50th-annual-meeting-on-women-s-cancer-7852582.html

[Warchest]

https://www.prnewswire.com/news-releases/leap-therapeutics-presents-at-society-of-gynecologic-oncology-50th-annual-meeting-on-womens-cancer-300813624.html

[BigDTrader32]

https://investors.leaptx.com/news-releases/news-release-details/leap-therapeutics-presents-society-gynecologic-oncology-50th

[crudeoil24]

Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
7:00 am ET March 18, 2019 (PR Newswire) Print
Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer. Patients, including those with carcinosarcoma and Wnt pathway alterations, have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of the study. The complete data set will become available in the coming months as the most recently enrolled patients have yet to be evaluated. The complete poster is available on Leap's website at https://www.leaptx.com/our-pipeline.

"We are very pleased with the single agent and combination activity of DKN-01 in this heavily pre-treated population. Allowing patients to achieve partial responses and durable stable disease with a favorable safety profile reflects meaningful clinical benefit," commented Rebecca C. Arend, M.D., Ph.D., Department of Obstetrics and Gynecology at the University of Alabama at Birmingham School of Medicine. "With the rapid enrollment of this study since the beginning of the year, we are looking forward to robust data maturing during the year."

"It is encouraging to see the mechanism-based strategy of enriching the study with patients with Wnt pathway alterations lead to impressive clinical outcomes," commented Michael Birrer, M.D., Ph.D., Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham. "We are also particularly interested in the early activity in carcinosarcoma patients, who are in need of new and better treatment options."

[Billa2k2]

When’s the results come in?

[Golden Cross]

Thinking $5+ easy if Phase 2 results are good. The buying alone might suggest it is good? We will see soon. GLTA

[LQMTinvestor2018]

If data is good I’m betting we see $5+!

[Golden Cross]

Chart looking real strong here.. Going to be watching this one.

[INTL]

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13228857&RcvdDate=2/14/2019&CoName=LEAP%20THERAPEUTICS%2C%20INC.&FormType=SC%2013G/A&View=html

[Bullwinkle77]

Anti-gravity

[INTL]

Loaded AH. Large volume and bullish movement. Volume beyond anything on chart. Great weekend everybody!

[INTL]

Why is this moving?

[ClayTrader]

* * $LPTX Video Chart 03-15-2019 * *

Link to Video - click here to watch the technical chart video

[ThatBigGuy]

If this closes green, it may launch on Monday based on news!

[TradeSmart.ai]

Weeeeee!!!! She’s still going boys!!! Love it!!! $LPTX

[NotTheFace1337]

This place is oddly quiet RN lol